Page 4 - ஆர்ஃபந் கிணறுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆர்ஃபந் கிணறுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆர்ஃபந் கிணறுகள் Today - Breaking & Trending Today

Gan & Lee receives EMA orphan drug designation for Phase I drug [...] | Comunicati stampa CataniaOggi

06 aprile 2021 13:40
Fonte: Adnkronos
#salute-e-benessere
-
BEIJING, and BRIDGEWATER, N.J., April 6, 2021 /PRNewswire/ Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007, for the treatment of glioma.
Glioma is a broad term describing neuroepithelial tumors originating from glial cells of the central nervous system, including astrocytic tumors such as glioblastomas (GBM). GBM is one of the most aggressive primary brain tumors and has median survival of 12 to 15 months, despite advances in surgery, chemotherapy, and radiation therapy1. Gan & Lee s current clinical development program for GLR2007, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, is investigating the treatment of advanced solid tumors which ....

Gina Antonucci , Michelle Mazuranic , Head Of Global Medical Affairs , Committee For Orphan Medicinal Products , Gan Lee Pharmaceuticals Co Ltd , European Union , Health Technology Assessments , European Commission , European Medicine Agency , Orphan Medicinal Products , Global Medical Affairs , Orphan Medicinal , Ganlee Fine , ஜினா அன்டோனூசி , தலை ஆஃப் உலகளாவிய மருத்துவ வாழ்க்கைத்தொழில்கள் , குழு க்கு ஆர்ஃபந் மருத்துவ ப்ராடக்ட்ஸ் , கண் லீ மருந்துகள் இணை லிமிடெட் , ஐரோப்பிய தொழிற்சங்கம் , ஆரோக்கியம் தொழில்நுட்பம் மதிப்பீடுகள் , ஐரோப்பிய தரகு , ஆர்ஃபந் மருத்துவ ப்ராடக்ட்ஸ் , உலகளாவிய மருத்துவ வாழ்க்கைத்தொழில்கள் , ஆர்ஃபந் மருத்துவ ,

'PDM is a political orphan'

Top Story
March 17, 2021
ISLAMABAD: Minister for Science and Technology Fawad Chaudhry said on Tuesday the government was working on initiation of contempt of court proceedings against the Election Commission of Pakistan (ECP) if it did not tender resignation.
He was briefing the media about the decisions taken at the cabinet meeting here, which met with Prime Minister Imran Khan in the chair after the election of the chairman and deputy chairman of Senate. The minister said consultations were held with the attorney general and they were working on the case that if the ECP chief election commissioner (CEC) and four provincial members did not step down, the government could initiate the contempt of court proceedings against them and also use all available options on that count. ....

Ali Muhammad , Nawaz Sharif , Aftab Sherpao , Awais Noorani , Muslim League Nawaz , Imran Khan , Maulana Fazlur Rehman , Asad Umar , Mehmood Achakzai , Election Commission Of Pakistan , Supreme Court , Pakistan People Party , Parliamentary Affairs Ali Muhammad Khan , Technology Fawad Chaudhry , Election Commission , Industries Muhammad Hammad Azhar , Pakistan Democratic Movement , Prime Minister Imran Khan , Industries Muhammad Hammad , Special Initiatives Asad Umar , Pakistan Muslim League Nawaz , Pakistan People , அலி முஹம்மது , நவாஸ் ஷெரிப் , ஆவிஸ் நூராணி , முஸ்லீம் லீக் நவாஸ் ,

Sangamo Therapeutics, Inc.: Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease

(3)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency s Committee for Orphan Medicinal Products (COMP) released details supporting the Orphan Designation of BIVV003, an investigational
ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase 1/2 PRECIZN-1 study partnered with Sanofi. The Committee s decision to grant Orphan Designation was based in part on early data from three patients that had 52 weeks, 13 weeks, and 29 days of follow-up, respectively.
In recently published minutes, the Committee considered the preliminary clinical observations of BIVV003 as well as the potential of long-term effects that may obviate the need for frequent treatment suggested a clinically relevant advantage. The Committee s published minutes report information on select patient characteristics for the first three patients treated, includin ....

Aaron Feingold , Exchange Commission , Sangamo Therapeutics Inc , Sangamo Therapeutics , European Medicines Agency , Orphan Medicinal Products , Orphan Designation , Annual Report , ஆரோன் பேன்கோல்த் , பரிமாற்றம் தரகு , சங்கமோ சிகிச்சை இன்க் , சங்கமோ சிகிச்சை , ஆர்ஃபந் மருத்துவ ப்ராடக்ட்ஸ் , ஆர்ஃபந் பதவி , ஆண்டு அறிக்கை ,

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer

(1)
TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).
In Japan, the estimated number of patients with uterine body cancer is approximately 30,000.1 It is estimated that in 2020, there were more than 17,000 new cases of uterine body cancer and more than 3,000 deaths from the disease.2 It is considered that more than 90% of uterine body cancers occur in the endometrium.3 ....

United States , Kostenloser Wertpapierhandel , Merck Co Inc , Eisai Co Ltd , Ministry Of Health , Public Relations Department , United Statesa , Relations Department , ஒன்றுபட்டது மாநிலங்களில் , மெர்க் இணை இன்க் , ேசை இணை லிமிடெட் , அமைச்சகம் ஆஃப் ஆரோக்கியம் , பொது உறவுகள் துறை , உறவுகள் துறை ,

Alkermes Announces Orphan Drug Designation For Nemvaleukin Alfa

WASHINGTON (dpa-AFX) - Alkermes plc (ALKS), a global biopharmaceutical company developing medicines in the fields of neuroscience and oncology, said nemvaleukin alfa, its investigational engineered ....

United States , Jessicca Rege , Vice President , ஒன்றுபட்டது மாநிலங்களில் , துணை ப்ரெஸிடெஂட் ,